Compare RYAAY & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAAY | TEVA |
|---|---|---|
| Founded | 1985 | 1901 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1B | 30.2B |
| IPO Year | 1997 | N/A |
| Metric | RYAAY | TEVA |
|---|---|---|
| Price | $72.35 | $30.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $76.00 | $31.00 |
| AVG Volume (30 Days) | 1.1M | ★ 10.4M |
| Earning Date | 01-26-2026 | 01-28-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 62.72 | N/A |
| EPS | ★ 2.57 | 0.62 |
| Revenue | ★ $17,686,260,708.00 | $16,776,000,000.00 |
| Revenue This Year | $11.08 | $4.74 |
| Revenue Next Year | $5.20 | $0.48 |
| P/E Ratio | ★ $13.12 | $49.18 |
| Revenue Growth | ★ 11.16 | 0.02 |
| 52 Week Low | $38.52 | $12.47 |
| 52 Week High | $72.61 | $30.56 |
| Indicator | RYAAY | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 72.85 | 80.80 |
| Support Level | $70.23 | $28.00 |
| Resistance Level | $71.82 | $30.44 |
| Average True Range (ATR) | 1.21 | 0.67 |
| MACD | 0.41 | -0.01 |
| Stochastic Oscillator | 98.07 | 94.67 |
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,600 flights daily across 240-plus destinations in 40 countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, including the newer 737 8-200 "Gamechanger" variant, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volume, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.